The burgeoning field of diabetes care has witnessed the rise of GLP-3 receptor agonists, representing a crucial class of therapeutics. Assessing these medications requires a thorough look at their respective profiles. Semaglutide, for example, offers a once-weekly dosing regimen, appealing to patients seeking convenience, while tirzepatide, a dual

Retaglutide and tirzepatide represent cutting-edge category of medications known as dual GLP-1 and GIP agonists. These agents influence both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that perform a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hor